Studies have shown that the factors predicting successful therapy with PD-1 antibody include the number of infiltrating lymphocytes in the tumor microenvironment, the expression of PD-L1 in the tumor, and the tumor mutation burden (TMB) (17). Here, PDCD1 is linked to neoplasm.